
Pulmonary Hypertension
Description
Pulmonary Hypertension
Global Pulmonary Arterial Hypertension Market to Reach $8.9 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Pulmonary Arterial Hypertension estimated at US$6.5 Billion in the year 2020, is projected to reach a revised size of US$8.9 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027. Prostacyclin & Prostacyclin Analogs, one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$4.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Endothelin Receptor Antagonists (ERAs) segment is readjusted to a revised 4.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 4.3% CAGR
The Pulmonary Arterial Hypertension market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 3.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
SGC Stimulators Segment to Record 5.3% CAGR
In the global SGC Stimulators segment, USA, Canada, Japan, China and Europe will drive the 5.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$393.2 Million in the year 2020 will reach a projected size of US$567.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Global Pulmonary Arterial Hypertension Market to Reach $8.9 Billion by 2027
In the changed post COVID-19 business landscape, the global market for Pulmonary Arterial Hypertension estimated at US$6.5 Billion in the year 2020, is projected to reach a revised size of US$8.9 Billion by 2027, growing at a CAGR of 4.6% over the analysis period 2020-2027. Prostacyclin & Prostacyclin Analogs, one of the segments analyzed in the report, is projected to record a 4.4% CAGR and reach US$4.5 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Endothelin Receptor Antagonists (ERAs) segment is readjusted to a revised 4.8% CAGR for the next 7-year period.
The U.S. Market is Estimated at $1.9 Billion, While China is Forecast to Grow at 4.3% CAGR
The Pulmonary Arterial Hypertension market in the U.S. is estimated at US$1.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2027 trailing a CAGR of 4.3% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.3% and 3.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.
SGC Stimulators Segment to Record 5.3% CAGR
In the global SGC Stimulators segment, USA, Canada, Japan, China and Europe will drive the 5.3% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$393.2 Million in the year 2020 will reach a projected size of US$567.1 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
Select Competitors (Total 46 Featured) -
- Abbott Laboratories
- Actelion Pharmaceuticals Ltd.
- AstraZeneca PLC
- Bayer Healthcare AG
- Boehringer Ingelheim International GmbH
- F. Hoffmann-La Roche AG
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- Novartis AG
- Pfizer, Inc.
- Teva Pharmaceutical Industries Ltd.
- United Therapeutics Corporation
- Vectura Group PLC
The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.
Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.
Table of Contents
196 Pages
- I. METHODOLOGY
- II. EXECUTIVE SUMMARY
- 1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Impact of Covid-19 and a Looming Global Recession
- Pulmonary Hypertension – Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- 2. FOCUS ON SELECT PLAYERS
- 3. MARKET TRENDS & DRIVERS
- 4. GLOBAL MARKET PERSPECTIVE
- TABLE 1: World Recent Past, Current & Future Analysis for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 2: World Historic Review for Pulmonary Hypertension by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 3: World 15-Year Perspective for Pulmonary Hypertension by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
- TABLE 4: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 5: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 6: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 7: World Recent Past, Current & Future Analysis for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 8: World Historic Review for Injectables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 9: World 15-Year Perspective for Injectables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 10: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 11: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 12: World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 13: World Recent Past, Current & Future Analysis for Endothelin Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 14: World Historic Review for Endothelin Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 15: World 15-Year Perspective for Endothelin Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 16: World Recent Past, Current & Future Analysis for Prostacyclin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 17: World Historic Review for Prostacyclin Analogs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 18: World 15-Year Perspective for Prostacyclin Analogs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 19: World Recent Past, Current & Future Analysis for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 20: World Historic Review for Phosphodiesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 21: World 15-Year Perspective for Phosphodiesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 22: World Recent Past, Current & Future Analysis for Soluble Guanylate Cyclase Stimulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 23: World Historic Review for Soluble Guanylate Cyclase Stimulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 24: World 15-Year Perspective for Soluble Guanylate Cyclase Stimulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
- TABLE 25: World Pulmonary Hypertension Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
- III. MARKET ANALYSIS
- UNITED STATES
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
- TABLE 26: USA Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 27: USA Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 28: USA 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 29: USA Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 30: USA Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 31: USA 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- CANADA
- TABLE 32: Canada Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 33: Canada Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 34: Canada 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 35: Canada Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 36: Canada Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 37: Canada 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- JAPAN
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
- TABLE 38: Japan Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 39: Japan Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 40: Japan 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 41: Japan Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 42: Japan Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 43: Japan 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- CHINA
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
- TABLE 44: China Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 45: China Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 46: China 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 47: China Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 48: China Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 49: China 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- EUROPE
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
- TABLE 50: Europe Recent Past, Current & Future Analysis for Pulmonary Hypertension by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
- TABLE 51: Europe Historic Review for Pulmonary Hypertension by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 52: Europe 15-Year Perspective for Pulmonary Hypertension by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
- TABLE 53: Europe Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 54: Europe Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 55: Europe 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 56: Europe Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 57: Europe Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 58: Europe 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- FRANCE
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
- TABLE 59: France Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 60: France Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 61: France 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 62: France Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 63: France Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 64: France 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- GERMANY
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
- TABLE 65: Germany Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 66: Germany Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 67: Germany 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 68: Germany Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 69: Germany Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 70: Germany 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- ITALY
- TABLE 71: Italy Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 72: Italy Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 73: Italy 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 74: Italy Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 75: Italy Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 76: Italy 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- UNITED KINGDOM
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
- TABLE 77: UK Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 78: UK Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 79: UK 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 80: UK Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 81: UK Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 82: UK 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- REST OF EUROPE
- TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 84: Rest of Europe Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 85: Rest of Europe 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 87: Rest of Europe Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 88: Rest of Europe 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- ASIA-PACIFIC
- Pulmonary Hypertension Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
- TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 90: Asia-Pacific Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 91: Asia-Pacific 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 93: Asia-Pacific Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 94: Asia-Pacific 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- REST OF WORLD
- TABLE 95: Rest of World Recent Past, Current & Future Analysis for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 96: Rest of World Historic Review for Pulmonary Hypertension by Type - Oral, Injectables and Inhalation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 97: Rest of World 15-Year Perspective for Pulmonary Hypertension by Type - Percentage Breakdown of Value Sales for Oral, Injectables and Inhalation for the Years 2012, 2021 & 2027
- TABLE 98: Rest of World Recent Past, Current & Future Analysis for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
- TABLE 99: Rest of World Historic Review for Pulmonary Hypertension by Mechanism of Action - Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
- TABLE 100: Rest of World 15-Year Perspective for Pulmonary Hypertension by Mechanism of Action - Percentage Breakdown of Value Sales for Endothelin Receptor Antagonists, Prostacyclin Analogs, Phosphodiesterase Inhibitors and Soluble Guanylate Cyclase Stimulators for the Years 2012, 2021 & 2027
- IV. COMPETITION
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.